fluorouracil has been researched along with Plasma Cell Tumor in 19 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We reported previously that treatment of mice bearing MOPC-315 plasmacytoma with the drugs L-PAM (phenylalanine mustard) or 5-FU (5-fluorouracil), in combination with low doses of THF-gamma 2, was more effective in increasing their survival time than treatment with the drug alone." | 3.68 | Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug. ( Ben-Efraim, S; Burstein, Y; Harshemesh, H; Ophir, R; Pecht, M; Trainin, N, 1991) |
| " In the present study the therapeutic effect and metabolism of 5-FU and its masked compounds: FT, UFT (uracil + FT), HCFU (Carmofur), 5'-DFUR (Doxifluridine) were assessed by using MOPC-104E plasmacytoma transplanted subcutaneously in BALB/c mice with CCl4-induced chronic liver dysfunction." | 3.68 | [Chemotherapy with fluoropyrimidines for MOPC-104E plasmacytoma transplanted in mice with CCl4 induced chronic liver dysfunction]. ( Imai, S; Morimoto, H; Nio, Y; Shiraishi, T; Tobe, T; Tseng, CC; Tsubono, M, 1990) |
| "Mice BDF1 with L 1210 or mice BALB/c with plasmacytoma MOPS-406 after pretreatment with ineffective doses of 1-beta-D-ribofuranosyl-4-methylmercaptopyrazolo(3,4-d)pyramidin e (25 to 100 mg/kg per 5 days) were treated with 5-fluorouracil at the optimal dose 100 mg per day." | 3.67 | [Enhanced antitumor action of 5-fluorouracil when used in combination with 4-methylmercaptopyrazolo[3,4-d]pyrimidine 1-nucleoside]. ( Garin, AM; Korbukh, IA; Lobova, TG; Preobrazhenskaia, MN, 1988) |
| " 5-FU oral bioavailability was approximately 100% in rats pretreated with 5-EU." | 1.29 | 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. ( Baccanari, DP; Davis, ST; Knick, VC; Spector, T, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (78.95) | 18.7374 |
| 1990's | 4 (21.05) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, D | 2 |
| Carbone, PP | 2 |
| Venditti, JM | 1 |
| Kline, I | 1 |
| Goldin, A | 1 |
| Teller, MN | 4 |
| Faanes, RB | 1 |
| Citarella, RV | 1 |
| Wallace, RE | 1 |
| Murdock, KC | 1 |
| Angier, RB | 1 |
| Durr, FE | 1 |
| Forbes, M | 1 |
| Baccanari, DP | 1 |
| Davis, ST | 1 |
| Knick, VC | 1 |
| Spector, T | 1 |
| Volm, M | 2 |
| Faufmann, M | 1 |
| MAttern, J | 2 |
| Wayss, K | 2 |
| Ophir, R | 3 |
| Pecht, M | 2 |
| Burstein, Y | 2 |
| Harshemesh, H | 1 |
| Ben-Efraim, S | 4 |
| Trainin, N | 2 |
| Tsubono, M | 2 |
| Nio, Y | 3 |
| Imai, S | 3 |
| Shiraishi, T | 3 |
| Morimoto, H | 2 |
| Tseng, CC | 2 |
| Kawabata, K | 1 |
| Fukumoto, M | 1 |
| Tobe, T | 3 |
| Ohgaki, K | 1 |
| Halperin, D | 1 |
| Rashid, G | 1 |
| Shoval, S | 2 |
| Lobova, TG | 1 |
| Korbukh, IA | 1 |
| Preobrazhenskaia, MN | 1 |
| Garin, AM | 1 |
| de Clercq, E | 1 |
| Wand, H | 1 |
| Rieche, K | 1 |
| Everson, R | 1 |
| Kessel, D | 1 |
| Hall, TC | 1 |
| Bowie, M | 3 |
| Mountain, IM | 1 |
| Stock, CC | 2 |
19 other studies available for fluorouracil and Plasma Cell Tumor
| Article | Year |
|---|---|
Evaluation of chemical agents against the plasma cell tumor LPC-1 in mice.
Topics: Alkylating Agents; Animals; Carcinoma 256, Walker; Cyclophosphamide; Electrophoresis; Fluorouracil; | 1967 |
Association of host immunity with 5-fluorouracil-initiated cure of plasmacytoma LPC-1 in BALB/c mice.
Topics: Animals; Antigens, Neoplasm; Cytotoxicity, Immunologic; Fluorouracil; Immunity, Cellular; Mice; Mice | 1980 |
Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Topics: Animals; Anthracenes; Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Drug Evaluat | 1982 |
5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.
Topics: Administration, Oral; Animals; Biological Availability; Colonic Neoplasms; Dihydrouracil Dehydrogena | 1993 |
Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Cricetinae; Da | 1975 |
Therapeutic effectiveness against MOPC-315 plasmacytoma of low or high doses of the synthetic thymic hormone THF-gamma 2 in combination with an "immunomodulating" or a "non-immunomodulating" drug.
Topics: Animals; Cell Line; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Immun | 1991 |
Low uracil concentration in the liver might be responsible for the decreased antineoplastic activity of fluoropyrimidines in mice with CCl4-induced chronic liver dysfunction.
Topics: Animals; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injury; Drug Resistance; Fi | 1991 |
[Chemotherapy with fluoropyrimidines for MOPC-104E plasmacytoma transplanted in mice with CCl4 induced chronic liver dysfunction].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbon Tetrachloride | 1990 |
Lymphocytes anticancer chemosensitivity testing in vitro--an approach to predict immunosuppressive effect of anticancer agents.
Topics: Animals; Antineoplastic Agents; Carbazilquinone; Doxorubicin; Fluorouracil; Immunosuppressive Agents | 1989 |
THF-gamma 2, a thymic hormone, increases immunocompetence and survival in 5-fluorouracil-treated mice bearing MOPC-315 plasmacytoma.
Topics: Animals; Antibody Formation; Concanavalin A; Fluorouracil; Immunocompetence; Interleukin-2; Male; Mi | 1989 |
The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.
Topics: Adjuvants, Immunologic; Animals; Concanavalin A; Cytotoxicity, Immunologic; Fluorouracil; Lymphocyte | 1986 |
[Enhanced antitumor action of 5-fluorouracil when used in combination with 4-methylmercaptopyrazolo[3,4-d]pyrimidine 1-nucleoside].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Eval | 1988 |
Enhancing effect of bromovinyldeoxyuridine on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Dose-Response Relationsh | 1986 |
[The effect of cytostatic drugs on blood platelets and lymphocytes in patients with neoplasms].
Topics: Adenine Nucleotides; Adenosine Diphosphate; Amidines; Antibiotics, Antineoplastic; Bleomycin; Blood | 1974 |
Enzymatic determinants of responsiveness of the LPC-1 plasma cell neoplasm to fluorouracil and fluorodeoxyuridine.
Topics: Animals; Cell Line; Disease Models, Animal; Floxuridine; Fluorouracil; Intestinal Neoplasms; Mice; N | 1970 |
The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cytarabine; Dauno | 1974 |
Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.
Topics: Allyl Compounds; Aniline Compounds; Animals; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, | 1974 |
Plasma cell tumors in experimental chemotherapy: consequence of dose variation on host survival and paraprotein synthesis.
Topics: Aniline Compounds; Animals; Blood Protein Disorders; Blood Protein Electrophoresis; Bloodletting; Cy | 1970 |
Transplantable mouse plasma cell tumors in experimental chemotherapy.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Blood Protein Electrophoresis; Blood Proteins; Ch | 1969 |